Share price · PMN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PMN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026-70.1%
Nothing announced by PMN that day or the session before.
- 28 Oct 2026+14.4%
Nothing announced by PMN that day or the session before.
- 27 Oct 2026+20.1%
Nothing announced by PMN that day or the session before.
- 21 Oct 2026+12.9%
Nothing announced by PMN that day or the session before.
- 9 Sep 2026+14.6%
Nothing announced by PMN that day or the session before.
- 28 Jul 2026+23.9%
- 23 Jul 2026-9.9%
Nothing announced by PMN that day or the session before.
- 17 Jul 2026+14.2%
Nothing announced by PMN that day or the session before.
- 30 Jun 2026+22.4%
Nothing announced by PMN that day or the session before.
- 9 Apr 2026+16.8%
Nothing announced by PMN that day or the session before.
Share of unusual movement by asset
For each asset, the share of PMN's own-move activity since 30 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
PMN310events and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 0% |
| Sessions with no dated event | — | 100% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Amyloid-beta (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease Early Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $6.7M | $44M+ <$0.1M short-term inv. | $8.2M-$9.4M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $9.5M | $53M+ <$0.1M short-term inv. | $12M-$10M operating cash flow | report ↗ |
| 2026-Q1 | — | $7.0M | $64M+ <$0.1M short-term inv. | $8.2M-$12M operating cash flow | report ↗ |
| 2025-Q3 | — | $9.8M | $15M+ <$0.1M short-term inv. | $12M-$10M operating cash flow | report ↗ |
| 2025-Q2 | — | $8.8M | $4.5M+ <$0.1M short-term inv. | $10M-$3.9M operating cash flow | report ↗ |
| 2025-Q1 | — | $5.5M | $8.4M+ <$0.1M short-term inv. | $7.3M-$4.9M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.6M | $22M+ <$0.1M short-term inv. | —-$6.7M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.6M | $1.0M+ <$0.1M short-term inv. | $2.6M-$1.5M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.1M | $2.5M+ <$0.1M short-term inv. | $3.6M-$10M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.1M | $17M+ <$0.1M short-term inv. | $2.4M-$2.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.0M | $1.2M+ <$0.1M short-term inv. | $2.3M-$2.1M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.5M | $3.3M+ <$0.1M short-term inv. | $5.0M-$2.6M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.6M | $3.9M+ <$0.1M short-term inv. | $6.0M-$4.6M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.2M | $8.9M+ <$0.1M short-term inv. | $2.8M-$4.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.9M | $14M | $2.1M-$3.4M operating cash flow | report ↗ |
| 2021-Q3 | — | $0.8M | $21M | $1.2M-$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $33M | $6.1M+ <$0.1M short-term inv. | $9.9M-$28M operating cash flow | report ↗ |
For 2025, ProMIS Neurosciences reported no revenue disclosure for the year or prior year, R&D expenses of $33.38M, up 213.7% YoY from $10.64M, cash and equivalents of $6.12M, and a net loss of $39.72M. No analyst consensus EPS comparison was provided.
The company guided that existing cash, following a February 2026 private placement with gross up-front proceeds of $75.5M as part of a financing of up to $175M, is expected to fund operations through 2027. PRECISE-AD Phase 1b was fully enrolled with 144 patients; six-month assessments are expected in Q2 2026, with a blinded interim analysis anticipated early Q3 2026 and top-line data in early 2027. PMN310 has maintained a favorable safety profile with no treatment-related serious adverse events reported, received FDA Fast Track designation in July 2025, and the company is advancing a subcutaneous formulation, with PMN267 and PMN442 in preclinical development for ALS and synucleinopathies.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $11M | $13M+ <$0.1M short-term inv. | —-$27M operating cash flow | report ↗ |
| 2023-FY | — | $7.9M | $13M+ <$0.1M short-term inv. | $3.3M-$11M operating cash flow | report ↗ |
| 2022-FY | — | $16M | $5.9M+ <$0.1M short-term inv. | $4.5M-$17M operating cash flow | report ↗ |
| 2021-FY | — | $4.6M | $17M+ <$0.1M short-term inv. | $2.5M-$9.3M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 11 purchases ($8.9M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-04 | Williams Eugene · director | Open-market purchase | 26,500 | $3.43 | $91K | Form 4 |
| 2026-11-02 | Cashman Neil · director, Chief Scientific Officer | Open-market purchase | 10,000 | $3.86 | $39K | Form 4 |
| 2026-10-30 | Williams Eugene · director | Open-market purchase | 1,316 | $3.99 | $5K | Form 4 |
| 2026-10-05 | Rubino Ivana · Chief Commercial Officer | Award / grant (derivative) | 80,000 | — | — | Form 4 |
| 2026-08-05 | Kaplan Johanne · Chief Development Officer | Open-market purchase | 2,280 | $13.30 | $30K | Form 4 |
| 2026-05-20 | Alex Slanix Paul · director | Award / grant (derivative) | 5,500 | — | — | Form 4 |
| 2026-05-20 | Kaplan Johanne · Chief Development Officer | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-05-20 | Mandel-Brehm Josh · director | Award / grant (derivative) | 5,500 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 25 reporting institutions held 6.1M shares ($78.0M, 68.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 1,292,757 | $16.4M |
| 2 | Deep Track Capital, LP | 835,655 | $10.6M |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 696,378 | $8.8M |
| 4 | Trails Edge Capital Partners, LP | 557,103 | $7.1M |
| 5 | Ally Bridge Group (NY) LLC | 414,219 | $5.3M |
| 6 | Woodline Partners LP | 395,295 | $5.0M |
| 7 | GREAT POINT PARTNERS LLC | 371,402 | $4.7M |
| 8 | Yu Fan | 329,760 | $4.2M |
| 9 | SPHERA FUNDS MANAGEMENT LTD. | 325,591 | $4.1M |
| 10 | Squadron Capital Management LLC | 324,977 | $4.1M |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 139,275 | $1.8M |
| 12 | ADAR1 Capital Management, LLC | 95,350 | $1.2M |
| 13 | 683 Capital Management, LLC | 92,850 | $1.2M |
| 14 | MILLENNIUM MANAGEMENT LLC | 77,921 | $990K |
| 15 | Empery Asset Management, LP | 60,353 | $766K |